Work

A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.tps9080

Authors: Kim Allyson Margolin, Hussein Abdul-Hassan Tawbi, Marc S. Ernstoff, F. Stephen Hodi, David F. McDermott, Robin Edwards, Alexandre Avila, Michael B. Atkins

Institutions: Stanford Medicine, University of Pittsburgh, UPMC Hillman Cancer Center, Cleveland Clinic, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb (United States), Georgetown Lombardi Comprehensive Cancer Center

Language: English

Topic: Brain Metastases and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2580016367

Cites:

Cited by: 4

Related to: 10